Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension

OBJECTIVE: Endothelin (ET) receptor antagonists (ERAs) have considerable improvements in pulmonary arterial hypertension (PAH) patients’ symptoms. Macitentan, a novel ERA, has more significant positive effects like reduction of morbidity and mortality in PAH patients by 45% and decreases PAH hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Nosrati, Marzieh, Shahmirzadi, Nikinaz Ashrafi, Afzali, Monireh, Zaboli, Pardis, Rouhani, Hasti, Hamedifar, Haleh, Hajimiri, Mirhamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567197/
https://www.ncbi.nlm.nih.gov/pubmed/33102342
http://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567197/
https://www.ncbi.nlm.nih.gov/pubmed/33102342
http://dx.doi.org/10.4103/jfmpc.jfmpc_1166_19

Ejemplares similares